170 related articles for article (PubMed ID: 33835335)
1. Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism.
Fahmy M; Sylvester KW; Migliore M; Eguale T; Fanikos J; Connors JM; Goldhaber SZ
J Thromb Thrombolysis; 2021 Jul; 52(1):22-29. PubMed ID: 33835335
[TBL] [Abstract][Full Text] [Related]
2. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
[TBL] [Abstract][Full Text] [Related]
3. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
[TBL] [Abstract][Full Text] [Related]
4. Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
Garland SG; DeRemer CE; Smith SM; Gums JG
Ann Pharmacother; 2018 Jun; 52(6):554-561. PubMed ID: 29338293
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
[No Abstract] [Full Text] [Related]
6. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
[TBL] [Abstract][Full Text] [Related]
7. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.
Cohen AT; Harrington R; Goldhaber SZ; Hull R; Gibson CM; Hernandez AF; Kitt MM; Lorenz TJ
Am Heart J; 2014 Mar; 167(3):335-41. PubMed ID: 24576517
[TBL] [Abstract][Full Text] [Related]
8. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
9. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
Miller KM; Brenner MJ
Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
[TBL] [Abstract][Full Text] [Related]
10. Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Escolar G; Díaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 Aug; 53(8):423-434. PubMed ID: 29119147
[TBL] [Abstract][Full Text] [Related]
11. Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
Ageno W; Lopes RD; Yee MK; Hernandez A; Hull RD; Goldhaber SZ; Gibson CM; Cohen AT
J Thromb Haemost; 2019 Dec; 17(12):2089-2098. PubMed ID: 31392827
[TBL] [Abstract][Full Text] [Related]
12. Betrixaban in the prevention of venous thromboembolism in medically ill patients.
Sylvester KW; Connors JM
Future Cardiol; 2018 Nov; 14(6):455-470. PubMed ID: 30353749
[TBL] [Abstract][Full Text] [Related]
13. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients.
Cave B; Hough A; Dobesh PP
Pharmacotherapy; 2018 Jun; 38(6):597-609. PubMed ID: 29543384
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.
Guy H; Laskier V; Fisher M; Neuman WR; Bucior I; Deitelzweig S; Cohen AT
Pharmacoeconomics; 2019 May; 37(5):701-714. PubMed ID: 30578462
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom.
Guy H; Laskier V; Fisher M; Bucior I; Deitelzweig S; Cohen AT
Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):259-267. PubMed ID: 31215264
[TBL] [Abstract][Full Text] [Related]
16. Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
Lee K; Cham S; Lam S
Cardiol Rev; 2018; 26(6):331-338. PubMed ID: 30067518
[TBL] [Abstract][Full Text] [Related]
17. Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.
Ageno W; Lopes RD; Yee MK; Hernandez A; Hull R; Goldhaber SZ; Gibson CM; Cohen AT
J Thromb Thrombolysis; 2020 Feb; 49(2):214-219. PubMed ID: 31493287
[TBL] [Abstract][Full Text] [Related]
18. The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients.
Scarpa D; Denas G; Babuin L; Pengo V
Expert Opin Pharmacother; 2019 Feb; 20(3):261-268. PubMed ID: 30615495
[TBL] [Abstract][Full Text] [Related]
19. Overview of betrixaban and its role in clinical practice.
Lekura J; Kalus JS
Am J Health Syst Pharm; 2018 Aug; 75(15):1095-1102. PubMed ID: 29941506
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.
MacDougall K; Spyropoulos AC
Semin Respir Crit Care Med; 2021 Apr; 42(2):308-315. PubMed ID: 33548931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]